10-Q quarterly report · filed Nov 10, 2026

CAPRICOR THERAPEUTICS, INC. (CAPR) Q3 2026 10-Q Quarterly Report

Short answer

CAPRICOR THERAPEUTICS, INC. (CAPR) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$43M
−73.6% YoY · −4.7% QoQ
EPS (diluted)
−$0.74
−37.0% YoY · −5.7% QoQ

Source: XBRL data from the CAPRICOR THERAPEUTICS, INC. (CAPR) Q3 2026 10-Q on SEC EDGAR. USD.

CAPRICOR THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no commercial products approved
  • Net loss $42.7M vs $24.6M YoY, R&D expense $29.6M vs $20.4M
  • Deramiocel spending $11.5M vs $7.3M, exosome research $0.7M vs $1.5M
  • Cash, equivalents, restricted cash and securities $198.5M vs $318.1M at December 31, 2025
  • FDA PDUFA date November 22, 2026, with additional funding needs and regulatory uncertainty ahead

Risk Factors

  • FDA Ad-Com vote 3-9 against Deramiocel effectiveness, extending PDUFA target date to November 22, 2026
  • NS arbitration, outcome could determine U.S. distribution rights and impose substantial costs
  • Premature commercialization and compliance spending, with new programs addressing Anti-Kickback and False Claims laws
  • No FDA-approved products, creating near-term launch and market-acceptance risk
  • Potential revenue concentration in Nippon Shinyaku, holding exclusive Deramiocel rights in the United States and Japan

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other CAPRICOR THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.